| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED NOVEMBER 2017. Refer to TA481: Immunosuppressive therapy for kidney transplant in adults for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | everolimus (Certican®) | |
| Formulation | 0.25 mg, 0.5 mg, 0.75 mg and 1 mg tablet | |
| Reference number | 431 | |
| Indication | Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal transplant |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 15/05/2015 | |
| Date of issue | 20/05/2015 | |
| NICE guidance | TA481: Immunosuppressive therapy for kidney transplant in adults |
|